Celgene Corp
CELG-Q
27 watching
About Celgene Corp (CELG-Q)
0
0
0
0
0
Your Reaction
(no dividend yield, Analysts' price target: not given) A global biotech focussed on cancer. They've stumbled recently, but phase 3 trials have been positive. Their drugs have a diminished chance of going generic, according to data. Attractive value. smart managers and a rich pipeline of drugs coming.
(no dividend yield, Analysts' price target: not given) A global biotech focussed on cancer. They've stumbled recently, but phase 3 trials have been positive. Their drugs have a diminished chance of going generic, according to data. Attractive value. smart managers and a rich pipeline of drugs coming.
They have a good cash float, which will lead to a share buyback, he feels. He sees resistance at $90-$100, which will be tough to battle through. He would suggest taking a loss if you hold this one, because the future capex requirements will be more expensive as interest rates rise. He would prefer IHI-N if you like the healthcare space as he does.
They have a good cash float, which will lead to a share buyback, he feels. He sees resistance at $90-$100, which will be tough to battle through. He would suggest taking a loss if you hold this one, because the future capex requirements will be more expensive as interest rates rise. He would prefer IHI-N if you like the healthcare space as he does.
They were working on some drug trials which didn't work as expected. Acqusitions didnt work out either The balance sheet is weaker than before. Some of their drugs will soon lose their patent.
They were working on some drug trials which didn't work as expected. Acqusitions didnt work out either The balance sheet is weaker than before. Some of their drugs will soon lose their patent.
Stock price has pushed up above the 200-day moving average. Longer term, this is an important space to be in. Good pipeline. Hold onto it at this point. Valuation is cheap. Trading at 9x earnings, expected 20% growth rate.
Stock price has pushed up above the 200-day moving average. Longer term, this is an important space to be in. Good pipeline. Hold onto it at this point. Valuation is cheap. Trading at 9x earnings, expected 20% growth rate.
(A Top Pick September 19, 2017. Down 37%). About 70% of the stocks he buys turn into gains. Celgene was one of the losses. Generally, the goal is to cut losses quickly. However, Celgene’s earnings have been rising, not falling. The difference is that the market has lost confidence in the company and dropped the valuation from a premium level to an extreme discount. The company has had some missteps, failed drug trials, that pare down its long term growth. Looking at Celgene at today’s price, he is keeping it because it offers good value at this price.
(A Top Pick September 19, 2017. Down 37%). About 70% of the stocks he buys turn into gains. Celgene was one of the losses. Generally, the goal is to cut losses quickly. However, Celgene’s earnings have been rising, not falling. The difference is that the market has lost confidence in the company and dropped the valuation from a premium level to an extreme discount. The company has had some missteps, failed drug trials, that pare down its long term growth. Looking at Celgene at today’s price, he is keeping it because it offers good value at this price.
Nice chart. Really nice base in May/June around $79. If it can stay above $83, it’s looking pretty good. Potential to consolidate around $100, as an end of year target. If it drops another $8, start reducing. Take a small position only.
Nice chart. Really nice base in May/June around $79. If it can stay above $83, it’s looking pretty good. Potential to consolidate around $100, as an end of year target. If it drops another $8, start reducing. Take a small position only.
The biotech sector is performing well. He would prefer to own the XBI-N ETF to get a basket and diversify risk.
The biotech sector is performing well. He would prefer to own the XBI-N ETF to get a basket and diversify risk.
It is turning around. It got hammered and is showing some potential. It looks like it is breaking the downtrend. He is keeping a sharp eye on it. He is optimistic.
It is turning around. It got hammered and is showing some potential. It looks like it is breaking the downtrend. He is keeping a sharp eye on it. He is optimistic.
Own widely. They had a number of missteps. They reduced their guidance. Great valuation. Some competitive threads coming in 2021-22. He would be cautious. (Analysts’ price target is $113.68)
Own widely. They had a number of missteps. They reduced their guidance. Great valuation. Some competitive threads coming in 2021-22. He would be cautious. (Analysts’ price target is $113.68)
He has started watching this bio-tech company as their earnings have been improving. The technical chart looks bearish to him now. He will watch them. (Analysts’ price target is $114)
He has started watching this bio-tech company as their earnings have been improving. The technical chart looks bearish to him now. He will watch them. (Analysts’ price target is $114)
This sector is fragmented and under valued. He likes it but has some short term issues that have hurt the stock. This is a negative momentum stock. Expects this to be higher in a year or 2. His favourite is Gilead in the sector.
This sector is fragmented and under valued. He likes it but has some short term issues that have hurt the stock. This is a negative momentum stock. Expects this to be higher in a year or 2. His favourite is Gilead in the sector.
He's long owned this. They has a nasty surprise in 2017 when a drug failed to get approval, plus other issues. Currently it's selling at 9x earnings. Firmly believe their new products--with big upside--will carry this company higher. (Analysts' price target: $111.83)
He's long owned this. They has a nasty surprise in 2017 when a drug failed to get approval, plus other issues. Currently it's selling at 9x earnings. Firmly believe their new products--with big upside--will carry this company higher. (Analysts' price target: $111.83)
(A Top Pick May 28/17, Down 32%) It is considered best of class but stumbled and there is a negative sentiment to health care stocks. It is growing double digits but trading at a single digit multiple so he is just holding it for now.
(A Top Pick May 28/17, Down 32%) It is considered best of class but stumbled and there is a negative sentiment to health care stocks. It is growing double digits but trading at a single digit multiple so he is just holding it for now.
Not cheap, based on its historic valuation. Fundamentally, it's a good business, but its chart is unhealthy. Healthcare should be in any portfolio and this is a quality company. But Celgene ranks near the bottom of his medical/health stocks, 45 out of 49.
Not cheap, based on its historic valuation. Fundamentally, it's a good business, but its chart is unhealthy. Healthcare should be in any portfolio and this is a quality company. But Celgene ranks near the bottom of his medical/health stocks, 45 out of 49.
Sold it a while ago. Looks cheap from a valuation standpoint trading at 9 times forward earning with a 19% growth rate. Investors are concerned about their cancer drugs patents expiring in a couple of years. Dark cloud surrounding the company.
Sold it a while ago. Looks cheap from a valuation standpoint trading at 9 times forward earning with a 19% growth rate. Investors are concerned about their cancer drugs patents expiring in a couple of years. Dark cloud surrounding the company.
They completed a $5 billion buyback recently. They put up a beat on recent earnings, but there were concerns about future earnings. He does not like the space as there is a wall of sellers to overcome and bio-tech is running out of technical momentum. They have great forecasted cash flow, but watch out if they miss their guidance.
They completed a $5 billion buyback recently. They put up a beat on recent earnings, but there were concerns about future earnings. He does not like the space as there is a wall of sellers to overcome and bio-tech is running out of technical momentum. They have great forecasted cash flow, but watch out if they miss their guidance.
We have some erosion here. You have to live with the overreaction. Around the $75 - $85 range there is probably a really good opportunity.
We have some erosion here. You have to live with the overreaction. Around the $75 - $85 range there is probably a really good opportunity.
A disappointment, having fallen on a number of missteps including negative trial results and management issues. With biotechs, the odds of getting a drug out of trials into production is small. So, it's best to have a stable of drugs and some of them will go through. Doesn't know if this is at a bottom here, but it should do well long-term. Carries an attractive below-10x earnings multiple.
A disappointment, having fallen on a number of missteps including negative trial results and management issues. With biotechs, the odds of getting a drug out of trials into production is small. So, it's best to have a stable of drugs and some of them will go through. Doesn't know if this is at a bottom here, but it should do well long-term. Carries an attractive below-10x earnings multiple.
It broke down in a lousy earnings report late last year. It broke its trend line, and more importantly the level of support at $97 has been broken. There is a lot of air or space now below this price. He is concerned about the look of it from a technical perspective. It might pop back up to its previous support level.
It broke down in a lousy earnings report late last year. It broke its trend line, and more importantly the level of support at $97 has been broken. There is a lot of air or space now below this price. He is concerned about the look of it from a technical perspective. It might pop back up to its previous support level.
Sticking with it. Valuations are too attractive to ignore. All they need are a few winning drugs and to offer proper guidance. Let's see some of their trials succeed--even good results will do. Their pipeline is too robust to stay at 8.5x forwarded earning. But management needs to regain credibility. (Analysts' target of $116.08)
Sticking with it. Valuations are too attractive to ignore. All they need are a few winning drugs and to offer proper guidance. Let's see some of their trials succeed--even good results will do. Their pipeline is too robust to stay at 8.5x forwarded earning. But management needs to regain credibility. (Analysts' target of $116.08)
(A Top Pick May 10/17, Down 26%) Was once a widely-owned, then despised, stock. New management came in, then there was a downrgade, then their Crohn's disease drug missed, then received an FDA letter for a mass drug is incomplete, which almost never happens. They've made a lot of mistakes in a short time. It still enjoys near-20% EPS growth. They have a dozen phase-two drugs in progress--a deep pipeline--but management has disappointed. That said, he continues to have faith in CELG.
(A Top Pick May 10/17, Down 26%) Was once a widely-owned, then despised, stock. New management came in, then there was a downrgade, then their Crohn's disease drug missed, then received an FDA letter for a mass drug is incomplete, which almost never happens. They've made a lot of mistakes in a short time. It still enjoys near-20% EPS growth. They have a dozen phase-two drugs in progress--a deep pipeline--but management has disappointed. That said, he continues to have faith in CELG.
Many growth opportunities but took some hits, falling from $150. Great opportunity now. FDA approval is coming up, so there's potential. 10.5x earnings. Could grow 15-20%. (Analysts' target of $116.32)
Many growth opportunities but took some hits, falling from $150. Great opportunity now. FDA approval is coming up, so there's potential. 10.5x earnings. Could grow 15-20%. (Analysts' target of $116.32)
Boasts 10-11x forward earnings with a 15% growth rate. FDA trial approvals would increase investor confidence further, but they have a good pipeline of products. Likes it longer term.
Boasts 10-11x forward earnings with a 15% growth rate. FDA trial approvals would increase investor confidence further, but they have a good pipeline of products. Likes it longer term.
(A Top Pick April 19/17. Down 14%.) This shot up to about $140, but a key new drug application was denied. That was followed by them announcing that their 3rd quarter was a little more difficult. They still have a plethora of new drug applications, and is still one of the hottest stocks in the sector. A very solid company.
(A Top Pick April 19/17. Down 14%.) This shot up to about $140, but a key new drug application was denied. That was followed by them announcing that their 3rd quarter was a little more difficult. They still have a plethora of new drug applications, and is still one of the hottest stocks in the sector. A very solid company.
(A Top Pick Nov 18/16. Down 16%.) Recently collapsed a bit, but still likes the name. Trading at 12X Forward Earnings with a 19% growth rate. That’s a .63 PEG ratio. They toned down guidance for 2020, and the concern is that they are going to be relying on their top cancer drug. Has been buying shares slowly. A cheap biotech name.
(A Top Pick Nov 18/16. Down 16%.) Recently collapsed a bit, but still likes the name. Trading at 12X Forward Earnings with a 19% growth rate. That’s a .63 PEG ratio. They toned down guidance for 2020, and the concern is that they are going to be relying on their top cancer drug. Has been buying shares slowly. A cheap biotech name.
One of the larger biotech companies. The big drop last month was due to a halt in one of their trials where they were developing what looked like a pretty good drug which would have been a big market. He would stay away for another month or so, but longer-term, it is a pretty good company with a portfolio of good drugs in development and good drugs in the market.
One of the larger biotech companies. The big drop last month was due to a halt in one of their trials where they were developing what looked like a pretty good drug which would have been a big market. He would stay away for another month or so, but longer-term, it is a pretty good company with a portfolio of good drugs in development and good drugs in the market.
(A Top Pick April 19/17. Down 18%.) Was one of the hottest stocks in the medical space. They have a plethora of new products in front of the FDA. It caught a cliff when 3 events happened. It was getting close to his target price of $150. One of the major analysts cut their price target which knocked it into the $130 range. FDA didn’t approve one of the new drugs knocking the price down into the $120 range. Missed a little on the 3rd quarter, so it dropped into the $100 range. He still likes it and is still buying.
(A Top Pick April 19/17. Down 18%.) Was one of the hottest stocks in the medical space. They have a plethora of new products in front of the FDA. It caught a cliff when 3 events happened. It was getting close to his target price of $150. One of the major analysts cut their price target which knocked it into the $130 range. FDA didn’t approve one of the new drugs knocking the price down into the $120 range. Missed a little on the 3rd quarter, so it dropped into the $100 range. He still likes it and is still buying.
(A Top Pick Nov 30/16. Down 14%.) Reported earlier this month. Just prior to reporting, took a phase 3 drug out of the pipeline, that had a lot of promise. It was a drug that treated Crohn’s disease. It will build back some of the confidence, but it will take time. The return opportunities are good enough to continue holding the position.
(A Top Pick Nov 30/16. Down 14%.) Reported earlier this month. Just prior to reporting, took a phase 3 drug out of the pipeline, that had a lot of promise. It was a drug that treated Crohn’s disease. It will build back some of the confidence, but it will take time. The return opportunities are good enough to continue holding the position.
This is revisiting old highs, which is a very bullish sign. In this case, it actually broke above its old highs. The current correction seems very healthy as long as it continues making higher lows. Add to your position, but keep a Stop at around $110.
This is revisiting old highs, which is a very bullish sign. In this case, it actually broke above its old highs. The current correction seems very healthy as long as it continues making higher lows. Add to your position, but keep a Stop at around $110.
(A Top Pick Oct 4/16. Up 38%.) One of the outstanding growth stocks in the US medical field. They have a plethora of new drugs coming out. Sales are growing at about 25% per annum. With the current earnings, the target price could move into the $165-$170 due to the growth rate. The company is more likely to surprise on the upside and another $1 of earnings could give you a $20-$25 a share. This could be a $200 stock. Still a Buy.
(A Top Pick Oct 4/16. Up 38%.) One of the outstanding growth stocks in the US medical field. They have a plethora of new drugs coming out. Sales are growing at about 25% per annum. With the current earnings, the target price could move into the $165-$170 due to the growth rate. The company is more likely to surprise on the upside and another $1 of earnings could give you a $20-$25 a share. This could be a $200 stock. Still a Buy.
This has done extremely well. It is growing quickly. Has a good pipeline with 4 drugs that he believes could be $1 billion or more in revenue. The biggest property they own is Revlimid. They concentrate on cancer treating drugs. Not inexpensive, but is reasonably priced. Thinks that next year they will do $8 a share in earnings, less than 20X, and growing at a rapid rate. (Analysts’ price target is $156.)
This has done extremely well. It is growing quickly. Has a good pipeline with 4 drugs that he believes could be $1 billion or more in revenue. The biggest property they own is Revlimid. They concentrate on cancer treating drugs. Not inexpensive, but is reasonably priced. Thinks that next year they will do $8 a share in earnings, less than 20X, and growing at a rapid rate. (Analysts’ price target is $156.)
(Top Pick Feb 22/17, Up 19%). They have a blood cancer drug. They are testing it on all kinds of other indications. They have the ability to double the revenues based on their existing products. It is the more growthy component of his portfolio.
(Top Pick Feb 22/17, Up 19%). They have a blood cancer drug. They are testing it on all kinds of other indications. They have the ability to double the revenues based on their existing products. It is the more growthy component of his portfolio.
This is big and is more diversified than others, so you are not buying a binary outcome stock. He likes biotech, but would approach it from the equal weight standpoint by going through the SPDR S&P Biotech ETF (XBI-N). Celgene is a good name.
This is big and is more diversified than others, so you are not buying a binary outcome stock. He likes biotech, but would approach it from the equal weight standpoint by going through the SPDR S&P Biotech ETF (XBI-N). Celgene is a good name.
(A Top Pick Oct 4/16. Up 28.79%.) Still loves this and has a target price of about $160 2-3 years out. It has some great products and has a whole plethora of new products before the FDA.
(A Top Pick Oct 4/16. Up 28.79%.) Still loves this and has a target price of about $160 2-3 years out. It has some great products and has a whole plethora of new products before the FDA.
Biotech stocks do really well this time of year from June 23 until September 13. Since 2002 they have been positive 88% of the time, and outperformed the S&P 500 88% of the time. July tends to be the best month for biotech stocks. The chart shows higher lows and a little bit of a break out. From a technical standpoint, this is positive. Very often, he will sell his biotech stocks later on in August.
Biotech stocks do really well this time of year from June 23 until September 13. Since 2002 they have been positive 88% of the time, and outperformed the S&P 500 88% of the time. July tends to be the best month for biotech stocks. The chart shows higher lows and a little bit of a break out. From a technical standpoint, this is positive. Very often, he will sell his biotech stocks later on in August.
(A Top Pick July 6/16. Up 31.77%.) This is still a Buy. It has cancer drugs that work. Very, very profitable. Amazing balance sheet. Very, very strong management team.
(A Top Pick July 6/16. Up 31.77%.) This is still a Buy. It has cancer drugs that work. Very, very profitable. Amazing balance sheet. Very, very strong management team.
(A Top Pick July 6/16. Up 16%.) Biotechnology company involved in cancer drugs. 20% earnings growth. Trading at 14X earnings. Strong balance sheet. Still a buy.
(A Top Pick July 6/16. Up 16%.) Biotechnology company involved in cancer drugs. 20% earnings growth. Trading at 14X earnings. Strong balance sheet. Still a buy.
He likes this. It closed at $116.41, and his model price is $145.80, a 25% upside. Maybe this gets down to $97, which would be an absolute Buy. Buy half a position now, and when it went cheaper, Buy the other half.
He likes this. It closed at $116.41, and his model price is $145.80, a 25% upside. Maybe this gets down to $97, which would be an absolute Buy. Buy half a position now, and when it went cheaper, Buy the other half.
They are growing nicely. One of the fastest growing large cap pharma in North America. Their slowest growth year was 14%. Otherwise they averaged 20% per year over the last 10 years. (Analysts’ target: $147) .
They are growing nicely. One of the fastest growing large cap pharma in North America. Their slowest growth year was 14%. Otherwise they averaged 20% per year over the last 10 years. (Analysts’ target: $147) .
(A Top Pick April 6/16. Up 8%.) Their cancer drug continues to do well. They have a strong pipeline behind that. The shares are trading at 15X forward earnings, with what he expects to be a 20% long-term growth rate. That gives a PEG ratio of .75. Still very cheap.
(A Top Pick April 6/16. Up 8%.) Their cancer drug continues to do well. They have a strong pipeline behind that. The shares are trading at 15X forward earnings, with what he expects to be a 20% long-term growth rate. That gives a PEG ratio of .75. Still very cheap.
Trading at 25X price to cash flow, a bit too rich for him. The stock is up 17% over the last 12 months. The bet on this company is that you have faith in their pipeline executing on future drugs. There is much more attractive value in healthcare outside of this.
Trading at 25X price to cash flow, a bit too rich for him. The stock is up 17% over the last 12 months. The bet on this company is that you have faith in their pipeline executing on future drugs. There is much more attractive value in healthcare outside of this.
(A Top Pick Feb 22/17. Up 14.45%.) One of the few companies that can double their revenue between now and 2020, without actually having pipeline success. Trading at 16X next year’s.
(A Top Pick Feb 22/17. Up 14.45%.) One of the few companies that can double their revenue between now and 2020, without actually having pipeline success. Trading at 16X next year’s.
They are able to double revenues between now and 2020 without a lot of pipeline success. The PEG ratio at .8, is not painful for a lot of their growth. Great financial metrics and you are not paying a lot for it. Some recent volatility presents a decent entry point. (Analysts’ price target is $146.)
They are able to double revenues between now and 2020 without a lot of pipeline success. The PEG ratio at .8, is not painful for a lot of their growth. Great financial metrics and you are not paying a lot for it. Some recent volatility presents a decent entry point. (Analysts’ price target is $146.)
One of the surest growth stocks out there. They have a product called Revlimid which treats a whole series of blood cancers. The one they have right now is multiple myeloma, and it prolongs people’s lives substantially. They are going to grow revenue 25% over the next 4 years. It is selling at 18X. Thinks it gets close to $200 in the next couple of years. (Analysts’ price target is $143.)
One of the surest growth stocks out there. They have a product called Revlimid which treats a whole series of blood cancers. The one they have right now is multiple myeloma, and it prolongs people’s lives substantially. They are going to grow revenue 25% over the next 4 years. It is selling at 18X. Thinks it gets close to $200 in the next couple of years. (Analysts’ price target is $143.)
He really likes this. If you look at all the biotechs, this has got the best pipeline of any. This is one you pick up on weakness. Earnings growth is very strong. Valuation is reasonable. Healthcare is probably a sector that shines in the 2nd half when we get through the Trump agenda.
He really likes this. If you look at all the biotechs, this has got the best pipeline of any. This is one you pick up on weakness. Earnings growth is very strong. Valuation is reasonable. Healthcare is probably a sector that shines in the 2nd half when we get through the Trump agenda.
Just added this in January. The company has a blood cancer drug that is really going to be the dominant player in that space. Has a huge pipeline of trials that are coming out with Revlimid . Also, diversifying their pipeline with Otezla. Between now and 2020, they are going to double revenues, and they don’t need success in their pipeline to do so. Trading at 16.9X forward earnings, and that grows down to 14X 24 months out. (Analysts’ price target is $140.27.)
Just added this in January. The company has a blood cancer drug that is really going to be the dominant player in that space. Has a huge pipeline of trials that are coming out with Revlimid . Also, diversifying their pipeline with Otezla. Between now and 2020, they are going to double revenues, and they don’t need success in their pipeline to do so. Trading at 16.9X forward earnings, and that grows down to 14X 24 months out. (Analysts’ price target is $140.27.)
They are a biotech large cap with a drug that has been one of their cash cows (50% of sales) and they are using that to bolster their pipeline. He really likes it. However, there are more attractive stocks in the healthcare space. There is better value to be had elsewhere in the space.
Heading into the election cycle, pharma will be under pressure. He prefers being into medical devices. He has a hard time being excited about either CELG or BMY, especially if the market is currently jittery. (Analysts’ price target is $100.33)